 |
| (L-R): John Walsh, President and Chief Executive Officer, Alpha-1 Foundation and John Perkins, Senior Vice President and General Manager, Portfolio Management and U.S. Business, Talecris Biotherapeutics |
The availability and engagement of patients and healthy volunteers are often rate-limiting factors in therapy development. By organizing patients and volunteers and partnering with companies, medical research foundations are accelerating the development of new drugs and diagnostics. Learn how nonprofits are serving as trusted brokers for public participation and setting best practices by building patient and control registries, clinical trials networks, and tissue banks.
Moderator:
Gregory Simon, Senior Vice President, Worldwide Policy, Pfizer, Inc
Speakers:
Peter Bell, Executive Vice President, Programs and Services Autism Speaks
Elizabeth Thompson, Vice President, Health Sciences
John Perkins, Senior Vice President and General Manager, Portfolio Management and U.S. Business, Talecris Biotherapeutics
John Walsh, President and Chief Executive Officer, Alpha-1 Foundation
Back to Program Schedule and Sessions |
